The expansion of a pharmaceutical company in Grangemouth will create 50 new jobs after a £45 million funding boost.
Piramal Pharma, based in India, is going to build two new Antibody- Drug Conjugate suits on its existing Earls Road site.
The site is expected to be completed by 2023 and will bring together more than 230 employees.
A new customer experience centre is also being constructed for clients who are visiting the site during development and/or manufacturing activities.
Scottish Enterprise is supporting the expansion and throwing £2.4 million into the project.
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, said: "We are delighted to announce the capacity expansion of our Grangemouth facility in the UK.
"This new development will more than double our ADC production capacity, strengthening our ability to service customers throughout the entire drug lifecycle.
"The primary driver behind this investment is the demand for commercial ADCs, coupled with a strong pipeline for clinical materials.
"This growth is a validation of Piramal Pharma Solutions’ strong focus on Patient Centricity, its proven track record of service delivery, and the strategic initiatives and deep customer relationships."
Adrian Gillespie, Chief Executive of Scottish Enterprise, said: "Piramal’s investment is tremendous news for Scotland’s life sciences sector, one of the largest life sciences clusters in Europe, and is creating new, high-quality jobs that are crucial to our economic recovery.
"With Scottish Enterprise support, the company’s Grangemouth site expansion proposals will deliver more R&D and production capacity for the development, scale up and commercial manufacture of drugs in the global fight against cancer."
